메뉴 건너뛰기




Volumn 28, Issue 3, 2009, Pages 328-333

Evaluation of cytotoxic effects of bevacizumab on human corneal cells

Author keywords

Avastin; Bevacizumab; Cornea; Neovascularization

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

EID: 67149139340     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31818b8be0     Document Type: Article
Times cited : (34)

References (24)
  • 2
    • 34247220899 scopus 로고    scopus 로고
    • Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier
    • Ambati BK, Patterson E, Jani P, et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol. 2007;91:505-508.
    • (2007) Br J Ophthalmol , vol.91 , pp. 505-508
    • Ambati, B.K.1    Patterson, E.2    Jani, P.3
  • 3
    • 33746621996 scopus 로고    scopus 로고
    • Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision
    • Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 11405-11410
    • Cursiefen, C.1    Chen, L.2    Saint-Geniez, M.3
  • 4
    • 0031965601 scopus 로고    scopus 로고
    • Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization
    • Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39: 18-22.
    • (1998) Invest Ophthalmol Vis Sci , vol.39 , pp. 18-22
    • Amano, S.1    Rohan, R.2    Kuroki, M.3
  • 5
    • 20444482034 scopus 로고    scopus 로고
    • Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo
    • Singh N, Amin S, Richter E, et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci. 2005;46:1647-1652.
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 1647-1652
    • Singh, N.1    Amin, S.2    Richter, E.3
  • 6
    • 0033856243 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
    • Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
    • (2000) Invest Ophthalmol Vis Sci , vol.41 , pp. 2514-2522
    • Philipp, W.1    Speicher, L.2    Humpel, C.3
  • 7
    • 0033941677 scopus 로고    scopus 로고
    • Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization
    • Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19:526-533.
    • (2000) Cornea , vol.19 , pp. 526-533
    • Cursiefen, C.1    Rummelt, C.2    Kuchle, M.3
  • 8
    • 33845968846 scopus 로고    scopus 로고
    • Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization
    • Singh N, Higgins E, Amin S, et al. Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea. 2007;26: 65-72.
    • (2007) Cornea , vol.26 , pp. 65-72
    • Singh, N.1    Higgins, E.2    Amin, S.3
  • 9
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 10
    • 23044505200 scopus 로고    scopus 로고
    • Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration
    • Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
    • (2005) Ophthalmic Surg Lasers Imaging , vol.36 , pp. 331-335
    • Rosenfeld, P.J.1    Moshfeghi, A.A.2    Puliafito, C.A.3
  • 11
    • 33646455655 scopus 로고    scopus 로고
    • Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection
    • Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26: 354-356.
    • (2006) Retina , vol.26 , pp. 354-356
    • Davidorf, F.H.1    Mouser, J.G.2    Derick, R.J.3
  • 12
    • 34247519047 scopus 로고    scopus 로고
    • Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
    • Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
    • (2007) Br J Ophthalmol , vol.91 , pp. 804-807
    • Manzano, R.P.1    Peyman, G.A.2    Khan, P.3
  • 13
    • 34247494559 scopus 로고    scopus 로고
    • Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
    • Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
    • (2007) Invest Ophthalmol Vis Sci , vol.48 , pp. 2545-2552
    • Bock, F.1    Onderka, J.2    Dietrich, T.3
  • 14
    • 34250315760 scopus 로고    scopus 로고
    • Topical bevacizumab therapy for corneal neovascularization
    • DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
    • (2007) Arch Ophthalmol , vol.125 , pp. 834-836
    • DeStafeno, J.J.1    Kim, T.2
  • 15
    • 34548722080 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for corneal neovascularization
    • Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1557-1559.
    • (2007) Graefes Arch Clin Exp Ophthalmol , vol.245 , pp. 1557-1559
    • Erdurmus, M.1    Totan, Y.2
  • 16
    • 47949107165 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis
    • Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
    • (2008) Cornea , vol.27 , pp. 743-745
    • Carrasco, M.A.1
  • 17
    • 38549140058 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab injection for corneal neovascularization
    • Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
    • (2008) Cornea , vol.27 , pp. 142-147
    • Bahar, I.1    Kaiserman, I.2    McAllum, P.3
  • 18
    • 38549107051 scopus 로고    scopus 로고
    • Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
    • Bock F, König Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246:281-284.
    • (2008) Graefes Arch Clin Exp Ophthalmol , vol.246 , pp. 281-284
    • Bock, F.1    König, Y.2    Kruse, F.3
  • 19
    • 35348978227 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for vascularized rejected corneal grafts
    • Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
    • (2007) J Cataract Refract Surg , vol.33 , pp. 1991-1993
    • Awadein, A.1
  • 20
    • 40449096035 scopus 로고    scopus 로고
    • Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome
    • Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
    • (2008) Cornea , vol.27 , pp. 70-73
    • Uy, H.S.1    Chan, P.S.2    Ang, R.E.3
  • 21
    • 0028953829 scopus 로고
    • An SV40-immortalized human corneal epithelial cell line and its characterization
    • Raki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
    • (1995) Invest Ophthalmol Vis Sci , vol.36 , pp. 614-621
    • Raki-Sasaki, K.1    Ohashi, Y.2    Sasabe, T.3
  • 22
    • 0024454325 scopus 로고
    • Quantification of cells cultured on 96-well plates
    • Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem. 1989;182:16-19.
    • (1989) Anal Biochem , vol.182 , pp. 16-19
    • Kueng, W.1    Silber, E.2    Eppenberger, U.3
  • 23
    • 33750285956 scopus 로고    scopus 로고
    • Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells
    • Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
    • (2006) Br J Ophthalmol , vol.90 , pp. 1316-1321
    • Spitzer, M.S.1    Wallenfels-Thilo, B.2    Sierra, A.3
  • 24
    • 67650578715 scopus 로고    scopus 로고
    • In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line
    • In press
    • Sharma RK, Chalam, KV. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol Scand. In press.
    • Acta Ophthalmol Scand
    • Sharma, R.K.1    Chalam, K.V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.